a 139

Aziridyl benzoquinone, an antineoplastic agent, has been studied as a mutagen and as a carcinogenic agent.

FGA139 is an inhibitor of cysteine proteases, specifically targeting cathepsin B and L with IC50 values of 4.98 μM and 3.14 μM, respectively. It reduces the production of NO in LPS-induced RAW264.7 cells and lowers TNFα levels in microglia, demonstrating antioxidant and anti-inflammatory properties. Additionally, FGA139 enhances the secretion of neuroprotective metabolites such as purines and linoleic acid in LPS-stimulated microglia. This compound is applicable in the study of neuroinflammatory diseases.

TD139 is a small molecule inhibitor of inhaled galectin-3 (Gal-3) with potential anti-fibrotic activity, commonly used in the study of idiopathic pulmonary fibrosis.

ELB-139 is a GABAA receptor agonist that can be used to study depression and epilepsy.

Antitumor agent-139 (compound 9b) is a gold (I) complex targeting liver and mitochondria, capable of generating reactive oxygen species (ROS) and facilitating DNA excretion. It inhibits tumor growth in patient-derived liver cancer xenograft models.

mmu-miR-139-3p Antagomir is modified with a high-affinity cholesterol group. This miRNA antagomir inhibits the function of mature miRNA by specifically binding to it, thereby preventing its complementary pairing with target genes. Compared to miRNA inhibitors, miRNA antagomirs demonstrate greater stability and inhibitory effectiveness in animal studies, and they more easily penetrate cellular membranes and tissue gaps, concentrating in target cells.

mmu-miR-139-3p Agomir is a specially chemically modified miRNA mimic, featuring methoxy modifications across the full length of the mature miRNA chain, with 2 and 4 thiophosphate linkages at the 5' and 3' ends, respectively, and a high-affinity cholesterol modification attached at the 3' end. This miRNA agomir mimics endogenous miRNA and enhances miRNA activity. Compared to regular mimics, miRNA agomirs show increased stability and inhibitory effects in animal experiments, and they more effectively penetrate cell membranes and tissue gaps to accumulate in target cells.

mmu-miR-139-3p mimic is a chemically synthesized miRNA analogue that simulates endogenous miRNA to enhance miRNA activity for gain-of-function research.

mmu-miR-139-3p inhibitor is a complementary single strand fully modified with methoxy to the mature miRNA. This miRNA inhibitor binds specifically to mature miRNA, preventing it from complementary pairing with target genes and thereby inhibiting miRNA function. It is useful for loss-of-function studies of miRNA.

Plp(139-151) trifluoroacetate is a useful organic compound for research related to life sciences and the catalog number is T64674.

Compound 6h (Anticancer Agent 139) exhibits potent anticancer activity, engaging in a π-cationic interaction with Lys352 of Tubulin and demonstrating high efficacy against SNB-19, OVCAR-8, and NCI-H460 with PGIs of 86.61, 85.26, and 75.99, respectively. Moreover, it shows moderate activity against a range of other cancer cell lines — HOP-62, SNB-75, ACHN, NCI/ADR-RES, 786-O, A549/ATCC, HCT-116, and MDA-MB-231 — with PGIs between 51.88 and 67.55 [1].

[Leu144,Arg147]-PLP (139-151) is a mutated fragment of the myelin proteolipid protein (PLP), featuring substitutions of tryptophan to leucine and histidine to arginine at positions 144 and 147, respectively. Immunizing mice with this peptide (50 µg) mixed in complete Freund's adjuvant (CFA) elevates IL-4 levels in the spleen. While it suppresses Th1 cell activation in vitro, it does not do so in vivo; instead, it promotes the development of regulatory T cells. Preimmunization with [Leu144, Arg147]-PLP (139-151) postpones the onset of experimental autoimmune encephalomyelitis (EAE) triggered by encephalitogenic peptides from PLP (178-191), myelin oligodendrocyte glycoprotein (MOG) (92-106), or myelin basic protein (MBP) in mice.

[SER140]-PLP(139-151) is a polypeptide fragment derived from the myelin-associated lipid protein.

[SER140]-PLP(139-151) acetate is a peptide fragment from myelin proteolipid protein (PLP).

[SER140]-PLP(139-151) (TFA) is a polypeptide fragment of the myelin lipid protein.

[L144-PLP(139-151)], a peptide ligand of the T cell receptor (TCR), acts as a TCR antagonist specifically inhibiting the activation of encephalitogenic Th1 clones [1].

CD36 Peptide P (139-155), Cys conjugated, a Cys-labelled variant of CD36 Peptide, can inhibit CD36's immunoadsorption by OKM5 [1].

E3 Ligase Ligand-linker Conjugate 139 is an E3 ubiquitin ligase ligand and linker for PROTACKB03-SLF, used in cancer research.

EGFR-IN-139 (compound PD 18) is an EGFR inhibitor with IC50 values of 12.88 nM (wild type), 10.84 nM (L858R/T790M), and 42.68 nM (L858R/T790M/C797S). It demonstrates significant anticancer activity against the A549 and H1975 cancer cell lines, which express high levels of EGFR. EGFR-IN-139 exhibits strong selectivity for cancer cells and can be utilized in research on non-small cell lung cancer (NSCLC).

SMW139 is a selective allosteric antagonist of the P2X7 receptor, exhibiting a Ki value of 32 nM for human P2X7R. In rat liver microsomes, its half-life is 47 minutes. SMW139 is applicable in research related to inflammation, Alzheimer's disease, and multiple sclerosis.

Antifungalagent 139 (Compound li) is an antifungal agent that demonstrates antifungal activity against Colletotrichum gloeosporioides by inhibiting CgSfu1 and CgRidA. It completely inhibits the growth of hyphae, conidial germination, and appressorium formation, with an EC50 of 18 μg/mL. Antifungalagent 139 effectively blocks the infection of host plants, such as tulip trees and cedar, by the pathogen. This compound is valuable for studying anthracnose disease.

PU139 is a novel inhibitor of histone acetyltransferase (HAT).

DK-139 is an inhibitor of NF-kappaB-mediated GROalpha expression, suppressing the TNFalpha-induced invasive capability of MDA-MB-231 human breast cancer cells.

Antibacterial agent 139 exhibits antibacterial activity specifically targeting Gram-positive bacteria, including resistant strains such as MRSA (anti-MRSA), VISA (anti-VISA), and LRSE (anti-LRSE). It operates by depolarizing the bacterial cell membrane [1].